Trethera

United States
Menasha, Wisconsin, United States, 90212

Company profile

Trethera company profile

Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.This approach is designed to overcome the limitations of single agent treatments and the associated risks of treatment failure and drug resistance. The combination therapy is addressing the alternative pathways of nucleotide biosynthesis, namely the de novo and the salvage pathways, as well as the mechanisms that protect the cancer genome against DNA replication stress and damage. The combination therapy causes an imbalance in the supply and demand of nucleotides which is lethal to cancer cells and well-tolerated by normal tissues.

Business identity

Contact email
[email protected]
Phone number
(310)997-2788
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2015-01-01, Year

Headquarters

Postal code
90212
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
9
Total equity funding
$7.7M
Last funding
Grant / $2.7M / 2025-12-16
Last equity funding
Series Unknown / $250,000
Investors
6
Lead investors
6
Founders
5
Articles
34

Founders and investors

Founders

Caius RaduDavid NathansonJohannes CzerninMichael JungOwen Witte

Lead investors

National Cancer InstituteNational Eye InstituteNational Institute of Allergy and Infectious DiseasesNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institute of HealthNational Institutes of Health

Investors

National Cancer InstituteNational Eye InstituteNational Institute of Allergy and Infectious DiseasesNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of Health